Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial

Simple summaryStereotactic body radiotherapy (SBRT) of 35–36.25 Gy in five fractions with the CyberKnife System yields excellent control with low toxicity in low–intermediate-risk prostate cancer patients. We found no differences in biochemical control and overall survival in relation to dose. There...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Valentina Borzillo, Esmeralda Scipilliti, Donato Pezzulla, Marcello Serra, Gianluca Ametrano, Giuseppe Quarto, Sisto Perdonà, Sabrina Rossetti, Sandro Pignata, Anna Crispo, Piergiacomo Di Gennaro, Valentina D’Alesio, Cecilia Arrichiello, Francesca Buonanno, Simona Mercogliano, Antonio Russo, Antonio Tufano, Rossella Di Franco, Paolo Muto
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-11-01
Colecção:	Frontiers in Oncology
Assuntos:	clinical outcome toxicity low-and intermediate-risk radiotherapy prostate cancer stereotactic body radiation
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1270498/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!